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in various human tumors when combined with cytotoxic chemother-
apy. In a phase II study, the combination of metronomic cyclo-
phosphamide with bevacizumab has shown promising activity in
recurrent ovarian cancer (Garcia et al., 2008). Although, metronomic
chemotherapeutic regimens have been used in a variety of solid tu-
mors, the data on patients with endometrial cancer is limited. Here,
we present two patients with advanced uterine cancer that were
treated with the combination of metronomic cyclophosphamide and
bevacizumab. Pathology type for the ﬁrst and secondwas endometrioid
and uterine papillary serous (UPSC), respectively.With this regimen theIntroduction
Targeting angiogenesis in order to achieve tumor control was intro-
duced by Folkman in 1971 (Folkman, 1971). Inhibition of angiogenesis
can be achieved with the use of targeted therapies that affect critical
steps in tumor vascularization or with the administration of cytotoxic
agents in a metronomic regimen. Conventional chemotherapy is typi-
cally administered in 3–4 week cycles at the maximal tolerated dose.
Metronomic chemotherapy is achieved by frequently administering
doses that are signiﬁcantly lower than the maximal tolerated dose. In
the time interval between consecutive cycles the host can recover
from adverse effects and the vascular damage can be rapidly repaired.
Although the cancer cells have less chance of recovering, regrowth of
part of the tumor can occur, especially if the drug-free period is too
long. It has been shown that shortening the drug-free period increases
the anti-angiogenic effects of cytotoxic drugs. An additional advantage
in continuous low-dose chemotherapy is the minimization of toxic
side-effects, while allowing combination with selective inhibitors of
angiogenesis (Mross and Steinbild, 2012).
Vascular endothelial growth factor (VEGF) is recognized as a major
element in regulating angiogenesis. In animal models, VEGF plays a
major role in mediating tumor growth while the VEGF monoclonal
antibody has an inhibitory effect. Bevacizumab, the recombinantoklyn, NY 11203, Box 25, USA.
is).
. This is an open access article underpatients achieved prolonged disease stabilization and improved quality
of life.
Case 1
A 56 year-old nulliparous black female initially presented with com-
plaints of irregular vaginal bleeding for the past 4 years and a 30 lb
weight loss over the course of 3 months. Physical exam showed an
obese woman with fullness of the right adnexa, 16-week uterus, mid-
line, enlarged cervix and gross tumor exiting the os. Family history
was unremarkable. An endometrial biopsy was obtained and revealed
moderately differentiated endometrial carcinoma of the endometrioid
type. CT abdomen and pelvis showed a left adnexal cystic/soft tissue
mass (9 × 9.6 cm), a left lower quadrant cystic mass (4.6 × 7.2 cm)
with amural nodule andmultiple hypodense hepatic lesions, the largest
measuring 2.2 × 2.5 cm, suggestive of metastatic disease. Tumor
markers were as follows: CA-125 1553 U/ml, CA 19-9 1491 U/ml and
CEA b0 .5 mcg/L. Given themultiple liver metastases, a primary optimal
cytoreduction was not considered feasible and the patient was offered
neoadjuvant chemotherapy with 3 cycles of carboplatin/paclitaxel
and plan for interval debulking. Imaging after the completion of the
chemotherapy course showed no interval change.
In addition, the patient had worsening bleeding requiring a blood
transfusion and the decision was made to proceed with surgical
management. The patient underwent an exploratory laparotomy, total
abdominal hysterectomy, bilateral salpingo-oopherectomy (BSO),
resection of peritoneal metastatic implant and a liver biopsy. The ﬁnd-
ings were as follows: 15 week uterus, 20 × 20 cm solid left adnexal
mass, along with a 5 × 8 cm peritoneal implant adjacent to the
left paracolic gutter and multiple lesions on the surface of the liver
consistent with metastases. The patient was suboptimally debulked
with residual disease at the liver. Final pathology was FIGO Grade IIthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A. CT Abdomen showsmultiple metastatic lesions (left). Stablemetastatic liver lesions after 12months of treatment withmetronomic cyclophosphamide and bevacizumab (right).
B. Disease stabilization with metronomic cyclophosphamide and bevacizumab in patient with advanced endometrioid adenocarcinoma as evidenced by CA-125 levels.
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and lymphovascular space invasion. Tumor size was 7.5 cm with in-
volvement of both the anterior and posterior aspect of the endometrial
cavity, cervical stroma, bilateral tubes and ovaries, left paracolic gutter
and the liver. The patient was assigned a FIGO (2009) stage IVB endo-
metrioid adenocarcinoma. Chemosensitivity studies (Precision Thera-
peutics) demonstrated resistance to all cytotoxic chemotherapeutics.
The patient was started on a metronomic regimen consisting of cyclo-
phosphamide 50 mg daily and bevacizumab 15 mg/kg every 3 weeks.
This regimen was in place for 16 months while disease stabilization
was achieved as evidenced by interval imaging (Fig. 1A). The sum of
longest dimensions of target lesions was 65 mm on baseline CT before
the initiation of the metronomic regimen, 55 mm after 6 months of
treatment and 61mmafter one year of treatment. Serial measurements
of CA-125 are consistentwith biochemical response to therapy (Fig. 1B).
During this time, the patient reported a good quality of life. The metro-
nomic therapy was interrupted due to a Stage IV non-healing decubitus
ulcer. Of note, the patient has been wheelchair bound for 10 years
secondary to a spine injury. Subsequently, her disease progressed rapid-
ly and she expired 2 months later.Case 2
A73year-old black female Para 3 initially presentedwith complaints
of abdominal pain, increased abdominal girth, nausea and vomiting for
oneweek. Physical exam showed an obesewomanwith a distended ab-
domen that was tender to palpation. Bowel sounds were hyperactive.
Pelvic exam revealed a 20-week size pelvic mass. Family history was
unremarkable. CT abdomen and pelvis showed small bowel obstruction
with transition point in the distal jejunum. There was a heterogeneous
mass measuring 7.3 × 6.5 cm extending from the uterus to the left ad-
nexa and causing small bowel obstruction. There was paraaortic, retro-
peritoneal and mesenteric lymphadenopathy. Multiple hypodensities
consistentwithmetastaseswere seen in both lobes of the liver, the larg-
est measuring 2 × 4 cm. CA-125 level was 135 U/ml. Given the clinical
picture of small bowel obstruction, the patient was taken to the operat-
ing room and underwent an exploratory laparotomy, radical hysterec-
tomy, BSO, tumor debulking, small bowel resection in 3 segments and
anastomosis, partial cystectomy, cystotomy repair and ureteral stent
placement, omentectomy, appendectomy, pelvic lymphadenectomy.
The operative ﬁndings were as follows: 10 × 20 × 20 cmmass involving
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appendix. Two tumor nodules measuring 2 cm each in the omentum.
Innumerable subcentimeter tumor nodules in the surface of the
liver. Three cm tumor plaque on the dome of the bladder. Gross
adenopathy in left pelvic sidewall. At the completion of surgery, there
was gross residual disease in the liver.
Histology was consistent with UPSC involving the small bowel,
omentum, appendix and bladder. Right tube and ovary, cervix,
parametria and lymph nodes were positive. Final pathology was Stage
IVB uterine papillary serous carcinoma. The treatment plan was
adjuvant chemotherapy with carboplatin and paclitaxel. One week
after the administration of the ﬁrst cycle the patient presented to the
emergency roomwith neutropenic urosepsis. Shewas treatedwith par-
enteral antibiotics (cefepime) and G-CSF (ﬁlgrastim). After she recov-
ered, she declined any further cytotoxic chemotherapy. At that time,
the option of metronomic chemotherapy with cyclophosphamide and
bevacizumab was discussed and the patient agreed to pursue the latter
treatment option.With themetronomic regimen, her disease remained
stable for 16months as evidenced by CA-125monitoring (Fig. 2) and CT
imaging. During that period of time the patient was asymptomatic.
Eventually, her disease progressed in the pelvis causing bilateral
obstructive nephropathy and the patient expired shortly thereafter.
Total survival time status-post surgery was 18 months.
Discussion
The combination chemotherapy with carboplatin and paclitaxel has
emerged as the treatment of choice for patients with advanced uterine
cancer (Miller et al., 2012). For patients with poor response to the
standard ﬁrst line treatment, the options are limited and there is no
standard of care regarding salvage treatment. Therapy typically
employs either second line cytotoxic chemotherapy or hormonal
agents. Based on data from GOG studies, cytotoxic chemotherapy for
advanced or recurrent disease provides a median progression free sur-
vival of 8 months and the goal of care is usually palliation (Fleming
et al., 2004). Moreover, the conventional chemotherapeutic regimens
use themaximum tolerated doses and are often associated with severe,
sometimes life threatening, side-effects.Fig. 2. Disease stabilization with metronomic cyclophosphamide and bTherefore, the introduction of new strategieswith at least equivalent
efﬁcacy and decreased toxicity is highly desirable. Metronomic chemo-
therapy is designed to maintain stable disease for advanced cancer
patients with minimal toxicity. It has been suggested that frequent ad-
ministering of low-dose chemotherapy targets the dividing endometrial
cells and inhibits the formation of tumor-associated capillaries. This
hypothesis is supported by in vitro data showing selective cytotoxicity
of low-dose chemotherapy for human vascular endothelial cells. Other
mechanismswhichhave been proposed include the induction of endog-
enous inhibitors of angiogenesis, the activation of apoptotic pathways
and the inhibition of recruitment of progenitor endothelial cells. The
daily low-dose cyclophosphamide has demonstrated remarkable efﬁca-
cy and tolerability in various animal models. Metronomic regimens
have been associated with favorable responses in patients with various
advanced solid tumors. A phase II study showed that the combination of
metronomic cyclophosphamide with bevacizumab can be effective and
well tolerated in patients with recurrent ovarian cancer. The response
rate in this study is favorably compared to other conventional or inves-
tigational treatment modalities for recurrent ovarian cancer (Garcia
et al., 2008).
The use of metronomic regimens in the treatment of advanced
uterine cancer is supported by in vitro data showing that angiogenesis
plays an important role in the growth of uterine tumors. Furthermore,
a higher expression of VEGF has been documented in malignant
compared to benign or hyperplastic endometrium (Abulaﬁa et al.,
1995). Limited clinical data on the use of the combination ofmetronom-
ic chemotherapy with bevacizumab in patients with advanced uterine
cancer who failed multiple conventional chemotherapies suggest the
potential for therapeutic beneﬁt (Wright et al., 2007). In our cases, the
progression free interval exceeds the previously reported median
progression free survival for patients treated with conventional or
investigational regimens.
Additionally, the patients continued to report a good quality of life
during their progression-free survival interval. None of the common
side effects of Bevacizumab such as hypertension and bowel perforation
occurred in our cases. Bevacizumab might have contributed to the non
healing decubitus ulcer in Case 1. Metronomic therapy is commonly
regarded as the ‘last resort’ for patients with advanced malignanciesevacizumab in a patient with UPSC as evidenced by CA-125 levels.
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anti-cancer treatment. One of the recognized beneﬁts of anti-angiogenic
therapies is control of ascites formation in patients with carcinomatosis
through the inhibition of malignant vascularization and stabilization of
tumor capillaries (Anon., 1995). In our case the tumors were purely
solid and they were stabilized with the anti-angiogenic therapy. Fre-
quently, concerns about the toxicity related to bevacizumab and cost
considerations lead providers to attempt a number of cytotoxic agents
before a metromonic regimen. This delay may have a negative impact
on the main objectives of metronomic treatment, which are disease
stabilization and maintenance of quality of life. The implementation of
the metronomic regimen relatively early in the course of the disease
while the patient is still in good performance status and before the
tumor load becomes overwhelming, may be associated with a higher
response rate.
Furthermore, starting themetronomic therapy earlymay reduce the
risk for life threatening toxicities of bevacizumab that are associated
with a higher tumor load like thromboembolism and bowel perforation.
The concept of early implementation of metronomic therapy is more
applicable in tumors with inherent resistance to cytotoxic chemothera-
py, like the endometrioid- type endometrial cancer.
In conclusion, the presented cases suggest that the combination of
metronomic cyclophosphamide with bevacizumab can be an effective
strategy against tumor progression in patients with advanced uterine
cancer when ﬁrst line chemotherapy fails. Controlled randomized trials
comparing conventional versus metronomic regimens are required inorder to deﬁne optimal drug combinations with maximal anti-tumor
activity and minimal toxicity.
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